gvtcx

NHS National Generic Pharmaceuticals Wave 13

ATAMIS LTD Published 19 Jan 2022 Contracts Finder

key details

Value£469,741,550
Statuscancelled
Category (CPV) 33600000
RegionEast Midlands, East of England, London, North East, North West, South East, South West, West Midlands, Yorkshire and the Humber
Deadline26 Jul 2021
Contract start1 Feb 2022
Contract end31 May 2024
Procedureopen
SME suitableYes
OCIDocds-b5fd17-3856df43-01d6-4042-a1e6-a1524397d100

Awards (231)

This procurement was awarded to 133 suppliers. Values shown are per-award; the notice total is £469,741,550.

SupplierValueDateStatus
Accord-UK Ltd shared £469,741,550 30 Nov 2021 active
Accord-UK Ltd shared £469,741,518 30 Nov 2021 active
ACIUM LTD shared £469,741,550 30 Nov 2021 active
ACIUM LTD shared £469,741,518 30 Nov 2021 active
Aguettant Ltd shared £469,741,550 30 Nov 2021 active
Aguettant Ltd shared £469,741,518 30 Nov 2021 active
Alissa Healthcare Research Limited shared £469,741,550 30 Nov 2021 active
Alissa Healthcare Research Limited shared £469,741,518 30 Nov 2021 active
Allergan shared £469,741,550 30 Nov 2021 active
Allergan shared £469,741,518 30 Nov 2021 active
Alliance Pharmaceuticals Limited shared £469,741,550 30 Nov 2021 active
Alliance Pharmaceuticals Limited shared £469,741,518 30 Nov 2021 active
Altan Pharma Ltd shared £469,741,550 30 Nov 2021 active
Altan Pharma Ltd shared £469,741,518 30 Nov 2021 active
Alturix shared £1 30 Nov 2021 active
Amarox Limited shared £469,741,550 30 Nov 2021 active
Amarox Limited shared £469,741,518 30 Nov 2021 active
AOP Orphan Ltd shared £469,741,550 30 Nov 2021 active
AOP Orphan Ltd shared £469,741,518 30 Nov 2021 active
Arcadia Pharma Ltd T/A Arcadia Medical shared £469,741,550 30 Nov 2021 active
Arcadia Pharma Ltd T/A Arcadia Medical shared £469,741,518 30 Nov 2021 active
Aristo Pharma Limited shared £469,741,550 30 Nov 2021 active
Aristo Pharma Limited shared £469,741,518 30 Nov 2021 active
Ascend Laboratories UK Ltd shared £469,741,550 30 Nov 2021 active
Ascend Laboratories UK Ltd shared £469,741,518 30 Nov 2021 active
Aspen Pharmacare UK Limited shared £469,741,550 30 Nov 2021 active
Aspen Pharmacare UK Limited shared £469,741,518 30 Nov 2021 active
Aspire Pharma Limited shared £469,741,550 30 Nov 2021 active
Aspire Pharma Limited shared £469,741,518 30 Nov 2021 active
ATNAHS PHARMA UK LIMITED shared £1 30 Nov 2021 active
Aventis Pharma ltd t/a Sanofi shared £469,741,550 30 Nov 2021 active
Aventis Pharma ltd t/a Sanofi shared £469,741,518 30 Nov 2021 active
Baxter Healthcare Ltd shared £469,741,550 30 Nov 2021 active
Baxter Healthcare Ltd shared £469,741,518 30 Nov 2021 active
Bayer Ltd shared £469,741,550 30 Nov 2021 active
Bayer Ltd shared £469,741,518 30 Nov 2021 active
B. Braun Medical Limited shared £469,741,550 30 Nov 2021 active
B. Braun Medical Limited shared £469,741,518 30 Nov 2021 active
Beaumont Pharma Ltd shared £1 30 Nov 2021 active
Bowmed Ibisqus Limited shared £469,741,550 30 Nov 2021 active
Bowmed Ibisqus Limited shared £469,741,518 30 Nov 2021 active
Bristol Laboratories Limited shared £469,741,550 30 Nov 2021 active
Bristol Laboratories Limited shared £469,741,518 30 Nov 2021 active
Brown & Burk UK Ltd shared £469,741,550 30 Nov 2021 active
Brown & Burk UK Ltd shared £469,741,518 30 Nov 2021 active
CHIESI LIMITED shared £1 30 Nov 2021 active
Cipla (EU) Ltd shared £469,741,550 30 Nov 2021 active
Cipla (EU) Ltd shared £469,741,518 30 Nov 2021 active
Clydesdale Pharma ltd shared £1 30 Nov 2021 active
Colonis Pharma Ltd shared £469,741,550 30 Nov 2021 active
Colonis Pharma Ltd shared £469,741,518 30 Nov 2021 active
Consilient Health Ltd shared £469,741,550 30 Nov 2021 active
Consilient Health Ltd shared £469,741,518 30 Nov 2021 active
Correvio GmbH shared £1 30 Nov 2021 active
Crescent Pharma Ltd shared £469,741,550 30 Nov 2021 active
Crescent Pharma Ltd shared £469,741,518 30 Nov 2021 active
CST Pharma Limited shared £469,741,550 30 Nov 2021 active
CST Pharma Limited shared £469,741,518 30 Nov 2021 active
Day Lewis Medical Ltd shared £469,741,550 30 Nov 2021 active
Day Lewis Medical Ltd shared £469,741,518 30 Nov 2021 active
Derma UK shared £469,741,550 30 Nov 2021 active
Derma UK shared £469,741,518 30 Nov 2021 active
Desitin Pharma Ltd shared £469,741,550 30 Nov 2021 active
Desitin Pharma Ltd shared £469,741,518 30 Nov 2021 active
Dexcel Pharma Ltd shared £469,741,550 30 Nov 2021 active
Dexcel Pharma Ltd shared £469,741,518 30 Nov 2021 active
Dr Falk Pharma UK Ltd shared £469,741,550 30 Nov 2021 active
Dr Falk Pharma UK Ltd shared £469,741,518 30 Nov 2021 active
Dr.Reddy's Laboratories (UK) Limited shared £469,741,550 30 Nov 2021 active
Dr.Reddy's Laboratories (UK) Limited shared £469,741,518 30 Nov 2021 active
Drugsrus Ltd shared £469,741,550 30 Nov 2021 active
Drugsrus Ltd shared £469,741,518 30 Nov 2021 active
ennogen healthcare ltd shared £469,741,550 30 Nov 2021 active
ennogen healthcare ltd shared £469,741,518 30 Nov 2021 active
Euro-Link Pharma Ltd shared £1 30 Nov 2021 active
FERNDALE PHARMACEUTICALS LIMITED shared £469,741,518 30 Nov 2021 active
Ferring Pharmaceuticals Ltd shared £469,741,550 30 Nov 2021 active
Ferring Pharmaceuticals Ltd shared £469,741,518 30 Nov 2021 active
Flexipharm Austrading Limited shared £469,741,550 30 Nov 2021 active
Flexipharm Austrading Limited shared £469,741,518 30 Nov 2021 active
FLYNN PHARMA LIMITED shared £1 30 Nov 2021 active
FOCUS PHARMACEUTICALS LIMITED shared £1 30 Nov 2021 active
Fontus Health Ltd shared £469,741,550 30 Nov 2021 active
Fontus Health Ltd shared £469,741,518 30 Nov 2021 active
Fresenius Kabi Limited shared £469,741,550 30 Nov 2021 active
Fresenius Kabi Limited shared £469,741,518 30 Nov 2021 active
GALEN LIMITED shared £1 30 Nov 2021 active
GlaxoSmithKline UK Limited shared £469,741,550 30 Nov 2021 active
GlaxoSmithKline UK Limited shared £469,741,518 30 Nov 2021 active
Glenmark Pharmaceuticals Europe Limited shared £469,741,550 30 Nov 2021 active
Glenmark Pharmaceuticals Europe Limited shared £469,741,518 30 Nov 2021 active
hameln pharma ltd shared £469,741,550 30 Nov 2021 active
hameln pharma ltd shared £469,741,518 30 Nov 2021 active
Healthcare Pharma Ltd shared £469,741,550 30 Nov 2021 active
Healthcare Pharma Ltd shared £469,741,518 30 Nov 2021 active
INTRAPHARM LABORATORIES LIMITED shared £1 30 Nov 2021 active
IPCA LABORATORIES UK LIMITED shared £1 30 Nov 2021 active
Kensington Pharma Ltd shared £469,741,550 30 Nov 2021 active
Kensington Pharma Ltd shared £469,741,518 30 Nov 2021 active
Kent Pharma Ltd shared £469,741,550 30 Nov 2021 active
Kent Pharma Ltd shared £469,741,518 30 Nov 2021 active
Kyowa Kirin Ltd shared £469,741,550 30 Nov 2021 active
Kyowa Kirin Ltd shared £469,741,518 30 Nov 2021 active
Laboratorio Reig Jofre SA shared £469,741,550 30 Nov 2021 active
Laboratorio Reig Jofre SA shared £469,741,518 30 Nov 2021 active
LEO Pharma shared £469,741,550 30 Nov 2021 active
LEO Pharma shared £469,741,518 30 Nov 2021 active
LogixX Pharma Ltd shared £469,741,550 30 Nov 2021 active
LogixX Pharma Ltd shared £469,741,518 30 Nov 2021 active
Lucane Pharma shared £469,741,550 30 Nov 2021 active
Lucane Pharma shared £469,741,518 30 Nov 2021 active
Lundbeck Limited shared £469,741,550 30 Nov 2021 active
Lundbeck Limited shared £469,741,518 30 Nov 2021 active
Lupin Healthcare (UK) Limited shared £469,741,550 30 Nov 2021 active
Lupin Healthcare (UK) Limited shared £469,741,518 30 Nov 2021 active
Macleods Pharma UK Limited shared £469,741,550 30 Nov 2021 active
Macleods Pharma UK Limited shared £469,741,518 30 Nov 2021 active
Macure Pharma ApS shared £469,741,550 30 Nov 2021 active
Macure Pharma ApS shared £469,741,518 30 Nov 2021 active
Manx Healthcare Ltd shared £469,741,550 30 Nov 2021 active
Manx Healthcare Ltd shared £469,741,518 30 Nov 2021 active
Martindale Pharma shared £469,741,550 30 Nov 2021 active
Martindale Pharma shared £469,741,518 30 Nov 2021 active
medac Pharma LLP shared £469,741,550 30 Nov 2021 active
medac Pharma LLP shared £469,741,518 30 Nov 2021 active
MEDLEY PHARMA LIMITED shared £1 30 Nov 2021 active
Medreich PLC shared £469,741,550 30 Nov 2021 active
Medreich PLC shared £469,741,518 30 Nov 2021 active
Merck Sharpe & Dohme (UK) Limited shared £469,741,550 30 Nov 2021 active
Merck Sharpe & Dohme (UK) Limited shared £469,741,518 30 Nov 2021 active
Mercury Pharmaceuticals Limited shared £469,741,550 30 Nov 2021 active
Mercury Pharmaceuticals Limited shared £469,741,518 30 Nov 2021 active
MIBE PHARMA UK LTD shared £1 30 Nov 2021 active
Milpharm Ltd/aurobinbdo shared £469,741,550 30 Nov 2021 active
Milpharm Ltd/aurobinbdo shared £469,741,518 30 Nov 2021 active
MIP Pharma GmbH shared £469,741,550 30 Nov 2021 active
MIP Pharma GmbH shared £469,741,518 30 Nov 2021 active
Morningside Pharmaeuticals shared £469,741,550 30 Nov 2021 active
Morningside Pharmaeuticals shared £469,741,518 30 Nov 2021 active
Mylan shared £469,741,550 30 Nov 2021 active
Mylan shared £469,741,518 30 Nov 2021 active
Napp Pharmaceuticals Ltd shared £469,741,550 30 Nov 2021 active
Napp Pharmaceuticals Ltd shared £469,741,518 30 Nov 2021 active
NECESSITY SUPPLIES LIMITED shared £1 30 Nov 2021 active
Neon Healthcare Ltd shared £469,741,550 30 Nov 2021 active
Neon Healthcare Ltd shared £469,741,518 30 Nov 2021 active
Nexcape Pharmaceuticals Ltd. shared £469,741,550 30 Nov 2021 active
Nexcape Pharmaceuticals Ltd. shared £469,741,518 30 Nov 2021 active
Norgine Pharmaceuticals Limited shared £469,741,550 30 Nov 2021 active
Norgine Pharmaceuticals Limited shared £469,741,518 30 Nov 2021 active
NORTHUMBRIA PHARMA LTD shared £1 30 Nov 2021 active
Noumed Life Sciences Limited shared £1 30 Nov 2021 active
Oralieve UK Ltd shared £1 30 Nov 2021 active
Organon Pharmaceuticals UK Ltd shared £469,741,550 30 Nov 2021 active
Organon Pharmaceuticals UK Ltd shared £469,741,518 30 Nov 2021 active
Panpharma UK Limited shared £469,741,550 30 Nov 2021 active
PANPHARMA UK LIMITED shared £1 30 Nov 2021 active
PARI shared £469,741,550 30 Nov 2021 active
PARI shared £469,741,518 30 Nov 2021 active
Pfizer Ltd shared £469,741,550 30 Nov 2021 active
Pfizer Ltd shared £469,741,518 30 Nov 2021 active
Phoenix Lab shared £1 30 Nov 2021 active
Pierre Fabre Ltd shared £469,741,550 30 Nov 2021 active
Pierre Fabre Ltd shared £469,741,518 30 Nov 2021 active
P M PHARMA LTD shared £1 30 Nov 2021 active
Profile Pharma Ltd shared £469,741,550 30 Nov 2021 active
Profile Pharma Ltd shared £469,741,518 30 Nov 2021 active
Ranbaxy UK shared £469,741,550 30 Nov 2021 active
Ranbaxy UK shared £469,741,518 30 Nov 2021 active
Reckitt Benckiser shared £469,741,550 30 Nov 2021 active
Reckitt Benckiser shared £469,741,518 30 Nov 2021 active
Recordati Pharmaceuticals shared £1 30 Nov 2021 active
Recordati Rare Diseases UK Ltd shared £469,741,550 30 Nov 2021 active
Recordati Rare Diseases UK Ltd shared £469,741,518 30 Nov 2021 active
Relonchem Ltd shared £469,741,550 30 Nov 2021 active
Relonchem Ltd shared £469,741,518 30 Nov 2021 active
Rivopharm UK Ltd shared £469,741,550 30 Nov 2021 active
Rivopharm UK Ltd shared £469,741,518 30 Nov 2021 active
Roche Products Ltd shared £469,741,550 30 Nov 2021 active
Roche Products Ltd shared £469,741,518 30 Nov 2021 active
Roma Pharmaceuticals Limited shared £469,741,550 30 Nov 2021 active
Roma Pharmaceuticals Limited shared £469,741,518 30 Nov 2021 active
Rosemont Pharmaceuticals Limited shared £469,741,550 30 Nov 2021 active
Rosemont Pharmaceuticals Limited shared £469,741,518 30 Nov 2021 active
RPH Pharmaceuticals AB shared £469,741,550 30 Nov 2021 active
RPH Pharmaceuticals AB shared £469,741,518 30 Nov 2021 active
Sandoz Ltd shared £469,741,550 30 Nov 2021 active
Sandoz Ltd shared £469,741,518 30 Nov 2021 active
SCIECURE PHARMA LIMITED shared £1 30 Nov 2021 active
Seacross Pharmaceuticals Ltd shared £469,741,550 30 Nov 2021 active
Seacross Pharmaceuticals Ltd shared £469,741,518 30 Nov 2021 active
Selective Supplies Ltd. shared £469,741,550 30 Nov 2021 active
Selective Supplies Ltd. shared £469,741,518 30 Nov 2021 active
SINTETICA LIMITED shared £1 30 Nov 2021 active
Sobi (Swedish Orphan Biovitrum Ltd) shared £1 30 Nov 2021 active
Stragen UK Ltd shared £469,741,550 30 Nov 2021 active
Stragen UK Ltd shared £469,741,518 30 Nov 2021 active
Strides Pharma Uk LTD shared £469,741,550 30 Nov 2021 active
Strides Pharma Uk LTD shared £469,741,518 30 Nov 2021 active
Synchrony shared £469,741,550 30 Nov 2021 active
Synchrony shared £469,741,518 30 Nov 2021 active
Syri Limited (T/A Thame Laboratories) shared £469,741,550 30 Nov 2021 active
Syri Limited (T/A Thame Laboratories) shared £469,741,518 30 Nov 2021 active
TAKEDA UK LIMITED shared £1 30 Nov 2021 active
TETRIS PHARMA LTD shared £1 30 Nov 2021 active
Teva UK Limited shared £469,741,550 30 Nov 2021 active
Teva UK Limited shared £469,741,518 30 Nov 2021 active
Thea Pharmaceuticals Limited shared £469,741,550 30 Nov 2021 active
Thea Pharmaceuticals Limited shared £469,741,518 30 Nov 2021 active
Thornton and Ross Ltd shared £469,741,550 30 Nov 2021 active
Thornton and Ross Ltd shared £469,741,518 30 Nov 2021 active
TILLOMED LABORATORIES LIMITED shared £1 30 Nov 2021 active
Torbay Pharmaceuticals shared £469,741,550 30 Nov 2021 active
Torbay Pharmaceuticals shared £469,741,518 30 Nov 2021 active
Torrent Pharma UK Ltd shared £469,741,550 30 Nov 2021 active
Torrent Pharma UK Ltd shared £469,741,518 30 Nov 2021 active
TRANSDERMAL LIMITED shared £1 30 Nov 2021 active
TYPHARM LIMITED shared £469,741,518 30 Nov 2021 active
UPJOHN UK LIMITED shared £1 30 Nov 2021 active
VANTAGE PHARMACEUTICALS LTD shared £1 30 Nov 2021 active
V Pharma shared £469,741,550 30 Nov 2021 active
V Pharma shared £469,741,518 30 Nov 2021 active
Waverley Pharma Europe Limited shared £469,741,550 30 Nov 2021 active
Waverley Pharma Europe Limited shared £469,741,518 30 Nov 2021 active
Waymade PLC shared £1 30 Nov 2021 active
Wockhardt UK Limited shared £469,741,550 30 Nov 2021 active
Wockhardt UK Limited shared £469,741,518 30 Nov 2021 active
Zentiva Pharma UK Ltd shared £469,741,550 30 Nov 2021 active
Zentiva Pharma UK Ltd shared £469,741,518 30 Nov 2021 active
Zista Pharma Ltd shared £469,741,550 30 Nov 2021 active
Zista Pharma Ltd shared £469,741,518 30 Nov 2021 active

description

Invitation to offer for NHS National Generic Pharmaceuticals Wave 13

Offer reference number: CM/PHG/17/5532

Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority's sole discretion) for a period or periods up to a total of 48 months.

Potential periods of call-offs under the framework agreement:

Transition (Everolimus)

CESW: 1 March 2022 - 30 September 2023 (19 months)

LSNE: 1 March 2022 - 31 January 2023 (11 months)

NWLN: 1 March 2022 - 31 January 2023 (11 months)

Oral Products plus non-parenterals

All Regions: 1 March 2022 - 31 May 2024 (27 months)

Hospital Only Products

CESW: 1 February 2022 - 30 September 2023 (20 months)

LSNE: 1 February 2022 - 31 May 2024 (28 months)

NWLN: 1 February 2022 - 31 January 2023 (12 months)

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

2 notices published against this procurement.

PublishedTypeRegimeNotice
19 Jan 2022 Tender cancelled (tenderCancellation) · 2b45447f-b07a-4024-8b3a-2a2f2fd86749-502293
3 Aug 2022 Award update (awardUpdate) · f872d76f-37e6-4b7e-b25e-c952ac8a42eb-560066

more from ATAMIS LTD

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.